{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:34:12Z","timestamp":1793410452852,"version":"4.5.0"},"reference-count":175,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jhep.2022.03.026","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T11:59:45Z","timestamp":1652702385000},"page":"1362-1378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":211,"title":["Impact of non-invasive biomarkers on hepatology practice: Past, present and future"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6715-8588","authenticated-orcid":false,"given":"Laurent","family":"Castera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.03.026_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0016-5085(19)35563-5","article-title":"One-second needle biopsy of the liver","volume":"35","author":"Menghini","year":"1958","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib6","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib7","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension:\u00a0report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib11","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.03.026_bib12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib13","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib14","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2022.01.011","article-title":"Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD","volume":"76","author":"Brunt","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of liver imaging and biopsy in clinical practice","volume":"377","author":"Tapper","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.03.026_bib16","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1572-0241.2001.03776.x","article-title":"Patient-administered nitrous oxide\/oxygen inhalation provides safe and effective analgesia for percutaneous liver biopsy: a randomized placebo-controlled trial","volume":"96","author":"Castera","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.03.026_bib20","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1053\/gast.1997.v113.pm9352863","article-title":"Noninvasive diagnosis of hepatic fibrosis or cirrhosis","volume":"113","author":"Oberti","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib21","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0140-6736(00)04258-6","article-title":"Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study","volume":"357","author":"Imbert-Bismut","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.03.026_bib22","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A\u00a0simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib23","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","article-title":"Transient elastography: a new noninvasive method for assessment of hepatic fibrosis","volume":"29","author":"Sandrin","year":"2003","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jhep.2022.03.026_bib24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrgastro.2016.86","article-title":"Critical comparison of elastography methods to assess chronic liver disease","volume":"13","author":"Friedrich-Rust","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib25","series-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource","year":"2016"},{"key":"10.1016\/j.jhep.2022.03.026_bib26","unstructured":"LITMUS: Liver Investigation: Testing Marker Utility in Steatohepatitis consortium (European Union IMI2-funded under Grant Agreement 777377). [cited 2022]; Available from: https:\/\/www.imi.europa.eu\/projects-results\/project-factsheets\/litmus."},{"key":"10.1016\/j.jhep.2022.03.026_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9121920","article-title":"Systematic review with meta-analysis: diagnostic accuracy of pro-C3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"9","author":"Mak","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jhep.2022.03.026_bib28","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"Mozes","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.03.026_bib29","first-page":"10","article-title":"FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis","author":"Vali","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhep.2022.03.026_bib30","first-page":"10","article-title":"Systematic review with meta-analyses: diagnostic accuracy of FibroMeter tests in patients with non-alcoholic fatty liver disease","author":"Van Dijk","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhep.2022.03.026_bib31","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib32","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib33","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0016-5085(88)80022-2","article-title":"Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis","volume":"95","author":"Williams","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1572-0241.1998.044_c.x","article-title":"AST\/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection","volume":"93","author":"Sheth","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib35","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1111\/j.1572-0241.2000.02322.x","article-title":"Need for validation of clinical decision aids: use of the AST\/ALT ratio in predicting cirrhosis in chronic hepatitis C","volume":"95","author":"Imperiale","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib36","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.03.026_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1665-2681(19)31807-1","article-title":"Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C","volume":"8","author":"Borsoi Viana","year":"2009","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jhep.2008.07.035","article-title":"Comparison of blood tests for liver fibrosis specific or not to NAFLD","volume":"50","author":"Cales","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1665-2681(19)31836-8","article-title":"AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis","volume":"7","author":"Loaeza-del-Castillo","year":"2008","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib40","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.03.026_bib41","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib42","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11695-007-9295-8","article-title":"The utility of the \"NAFLD fibrosis score\" in morbidly obese subjects with NAFLD","volume":"18","author":"Qureshi","year":"2008","journal-title":"Obes Surg"},{"key":"10.1016\/j.jhep.2022.03.026_bib44","first-page":"1682","article-title":"Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis","volume":"103","author":"Wong","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib45","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","article-title":"Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials","volume":"70","author":"Anstee","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib46","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/MEG.0b013e32835d72cf","article-title":"Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?","volume":"25","author":"McPherson","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib47","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib48","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1478-3231.2005.01064.x","article-title":"Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"25","author":"Suzuki","year":"2005","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.03.026_bib49","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00535-007-2014-3","article-title":"Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage","volume":"42","author":"Yoneda","year":"2007","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib50","first-page":"201","article-title":"Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis","volume":"10","author":"Lesmana","year":"2009","journal-title":"J\u00a0Dig Dis"},{"key":"10.1016\/j.jhep.2022.03.026_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hep.26030","article-title":"Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease","volume":"57","author":"Tanwar","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib52","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000439083","article-title":"Tissue inhibitors of metalloproteinase-1 and 2 and obesity related non-alcoholic fatty liver disease: is there a relationship","volume":"92","author":"Abdelaziz","year":"2015","journal-title":"Digestion"},{"key":"10.1016\/j.jhep.2022.03.026_bib53","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jhep.2007.02.003","article-title":"Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies","volume":"46","author":"Hemmann","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib54","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.jhep.2022.03.026_bib55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1042\/bj2320145","article-title":"Purification and characterization of the N-terminal propeptide of human type III procollagen","volume":"232","author":"Niemela","year":"1985","journal-title":"Biochem J"},{"key":"10.1016\/j.jhep.2022.03.026_bib56","doi-asserted-by":"crossref","first-page":"G1009","DOI":"10.1152\/ajpgi.00283.2016","article-title":"Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy","volume":"311","author":"Karsdal","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jhep.2022.03.026_bib57","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhepr.2019.06.004","article-title":"Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease","volume":"1","author":"Boyle","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.03.026_bib58","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: a cohort study","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib59","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.21984","article-title":"Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers","volume":"47","author":"Guha","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-230X-6-6","article-title":"Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"6","author":"Ratziu","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib61","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/apt.13770","article-title":"Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference","volume":"44","author":"Munteanu","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.03.026_bib62","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients\u00a0with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.09.026","article-title":"ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD","volume":"76","author":"Corey","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe8939","article-title":"Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors","volume":"13","author":"Cazanave","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2022.03.026_bib65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.2005.069153","article-title":"Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study","volume":"55","author":"Foucher","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.03.026_bib66","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib67","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib68","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib69","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jhep.2016.04.023","article-title":"Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease","volume":"65","author":"Boursier","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib70","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S2468-1253(18)30124-9","article-title":"Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis","volume":"3","author":"Nguyen-Khac","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib71","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.23425","article-title":"Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations","volume":"51","author":"Castera","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib72","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib73","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib74","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib75","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.27362","article-title":"Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study","volume":"60","author":"Loomba","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib76","article-title":"Baveno VII - renewing consensus in portal hypertension","author":"de Franchis","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib77","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib78","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ultrasmedbio.2016.07.025","article-title":"A\u00a0meta-analysis for the diagnostic performance of transient elastography for clinically significant portal hypertension","volume":"43","author":"You","year":"2017","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jhep.2022.03.026_bib79","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.03.026_bib80","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cgh.2019.04.062","article-title":"Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"17","author":"Stafylidou","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib81","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fphys.2019.01028","article-title":"Baveno criteria safely identify patients with compensated advanced chronic liver disease who can avoid variceal screening endoscopy: a diagnostic test accuracy meta-analysis","volume":"10","author":"Szakacs","year":"2019","journal-title":"Front Physiol"},{"key":"10.1016\/j.jhep.2022.03.026_bib82","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/liv.14334","article-title":"Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B","volume":"40","author":"Voulgaris","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.03.026_bib83","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib84","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.30946","article-title":"The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib85","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstrom","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib86","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.cgh.2020.09.044","article-title":"Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD","volume":"19","author":"Gidener","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib87","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.16745","article-title":"Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality","volume":"55","author":"Higuchi","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.03.026_bib88","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib89","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib90","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib91","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib92","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib93","series-title":"Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection","year":"2015"},{"key":"10.1016\/j.jhep.2022.03.026_bib94","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A\u00a0morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib95","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2021.09.013","article-title":"Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR","volume":"76","author":"D'Ambrosio","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib96","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.03.026_bib97","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cgh.2017.04.038","article-title":"Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib98","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib99","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.31588","article-title":"A\u00a0model based on noninvasive markers predicts very low hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis","volume":"72","author":"Alonso Lopez","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib100","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 Years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib101","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","article-title":"Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals","volume":"72","author":"Pons","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib102","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1053\/j.gastro.2021.10.051","article-title":"Expert panel review\u00a0to compare FDA and EMA guidance on drug development and endpoints in nonalcoholic steatohepatitis","volume":"162","author":"Loomba","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib103","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib104","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","article-title":"Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD","volume":"18","author":"Tamaki","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jhep.2022.03.026_bib105","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib106","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib107","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1136\/gutjnl-2020-322976","article-title":"MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"70","author":"Jung","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.03.026_bib108","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.32145","article-title":"Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis","volume":"75","author":"Tamaki","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib109","article-title":"Two-step strategy, FIB-4 followed by magnetic resonance elastography, for\u00a0detecting advanced fibrosis in NAFLD","author":"Tamaki","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib110","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S2468-1253(20)30252-1","article-title":"A\u00a0blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study","volume":"5","author":"Harrison","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib111","doi-asserted-by":"crossref","first-page":"100409","DOI":"10.1016\/j.jhepr.2021.100409","article-title":"Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: diagnostic and mechanistic relevance","volume":"4","author":"Johnson","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.03.026_bib112","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib113","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib114","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib115","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib116","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.32163","article-title":"Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases","volume":"75","author":"Gines","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib117","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-230X-10-40","article-title":"Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)","volume":"10","author":"Poynard","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib118","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1136\/gut.2010.221382","article-title":"Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years","volume":"60","author":"Roulot","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.03.026_bib119","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.cgh.2017.12.048","article-title":"High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study","volume":"16","author":"Caballeria","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib120","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003193","article-title":"The application of liver stiffness measurement in residents without overt liver diseases through a community-based screening program","volume":"95","author":"Cheng","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2022.03.026_bib121","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/j.gastro.2019.09.008","article-title":"Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease","volume":"158","author":"Hagstrom","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.03.026_bib122","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.27981","article-title":"Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study","volume":"63","author":"Koehler","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib123","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/gutjnl-2011-300342","article-title":"Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.03.026_bib124","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/apt.14463","article-title":"Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography","volume":"47","author":"Harman","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.03.026_bib125","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.14309\/ajg.0000000000000357","article-title":"Obesity is the most common risk factor for chronic liver disease: results from a risk stratification pathway using transient elastography","volume":"114","author":"Harris","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib126","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ueg2.12109","article-title":"High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort","volume":"9","author":"Llop","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2022.03.026_bib127","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/liv.13743","article-title":"Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population","volume":"38","author":"Petta","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.03.026_bib128","article-title":"Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: results from NHANES 2017-2018","volume":"16","author":"Zhang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.03.026_bib129","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jama.2012.186","article-title":"Does this patient with liver disease have cirrhosis?","volume":"307","author":"Udell","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2022.03.026_bib130","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","article-title":"Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia","volume":"71","author":"Serra-Burriel","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib131","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2468-1253(16)30081-4","article-title":"Screening for liver fibrosis in the general population: a call for action","volume":"1","author":"Gines","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib132","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S2468-1253(18)30077-3","article-title":"Non-alcoholic fatty liver disease and the interface between primary and secondary care","volume":"3","author":"Tsochatzis","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib133","article-title":"A\u00a0global survey of physicians knowledge about nonalcoholic fatty liver disease","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib134","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/ajg.2014.134","article-title":"Nonalcoholic fatty liver disease is underrecognized in the primary care setting","volume":"110","author":"Blais","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2022.03.026_bib135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/liv.14347","article-title":"Non-invasive tests for liver fibrosis in NAFLD: creating pathways between primary healthcare and liver clinics","volume":"40","author":"Castera","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.03.026_bib136","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/apt.14219","article-title":"Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD","volume":"46","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.03.026_bib137","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jhep.2019.04.020","article-title":"New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD","volume":"71","author":"Boursier","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib138","article-title":"Non-invasive algorithms for the case finding of \u201cat-risk\u201d patients with NAFLD","author":"Castera","year":"2022","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2022.03.026_bib139","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib140","doi-asserted-by":"crossref","first-page":"100293","DOI":"10.1016\/j.jhepr.2021.100293","article-title":"Embedding assessment of liver fibrosis into routine diabetic review in primary care","volume":"3","author":"Mansour","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.03.026_bib141","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.cgh.2020.04.017","article-title":"Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system","volume":"18","author":"Vilar-Gomez","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib142","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/liv.14198","article-title":"Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: diagnostic accuracy and cost analysis","volume":"39","author":"Crossan","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.03.026_bib143","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2022.03.026_bib144","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib145","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib146","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.2337\/dc21-S004","article-title":"Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2022.03.026_bib147","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib148","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","article-title":"Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study","volume":"65","author":"Kwok","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.03.026_bib149","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/jgh.14577","article-title":"Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography","volume":"34","author":"Lai","year":"2019","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib150","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2022.03.026_bib151","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejim.2020.08.005","article-title":"Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study","volume":"82","author":"Mikolasevic","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jhep.2022.03.026_bib152","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/liv.13481","article-title":"Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan","volume":"37","author":"Roulot","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.03.026_bib153","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.03.026_bib154","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib155","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2022.03.026_bib156","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A\u00a0protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.03.026_bib157","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.31535","article-title":"Genome-wide association study and meta-analysis on alcohol-associated liver cirrhosis identifies genetic risk factors","volume":"73","author":"Schwantes-An","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib158","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A\u00a0genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2022.03.026_bib159","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1038\/ncomms5309","article-title":"TM6SF2 rs58542926 influences hepatic fibrosis progression in patients\u00a0with non-alcoholic fatty liver disease","volume":"5","author":"Liu","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2022.03.026_bib160","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib161","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","article-title":"Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma","volume":"61","author":"Liu","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib162","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1038\/s41598-017-04991-0","article-title":"MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals","volume":"7","author":"Donati","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.03.026_bib163","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib164","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2021.10.005","article-title":"A\u00a0genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers","volume":"76","author":"Whitfield","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib165","doi-asserted-by":"crossref","first-page":"12541","DOI":"10.1038\/s41598-019-48746-5","article-title":"Gene expression predicts histological severity and reveals distinct molecular profiles of nonalcoholic fatty liver disease","volume":"9","author":"Hoang","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2022.03.026_bib166","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4448","article-title":"Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis","volume":"12","author":"Govaere","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2022.03.026_bib167","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/hep.31995","article-title":"Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis","volume":"74","author":"Kozumi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.03.026_bib168","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib169","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cmet.2020.11.010","article-title":"Current concepts, opportunities, and challenges of gut microbiome-based personalized\u00a0medicine in nonalcoholic fatty liver disease","volume":"33","author":"Sharpton","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2022.03.026_bib170","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41575-018-0058-x","article-title":"Gut microbiome, microbial metabolites and the development of NAFLD","volume":"15","author":"Caussy","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib171","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2022.03.026_bib172","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","article-title":"A\u00a0universal gut-microbiome-derived signature predicts cirrhosis","volume":"32","author":"Oh","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2022.03.026_bib173","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cgh.2018.08.065","article-title":"Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function","volume":"17","author":"Sharpton","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib174","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.03.026_bib175","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1373\/clinchem.2005.048389","article-title":"Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection","volume":"51","author":"Adams","year":"2005","journal-title":"Clin Chem"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822002008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822002008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:44:54Z","timestamp":1759175094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822002008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":175,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0168827822002008"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.03.026","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of non-invasive biomarkers on hepatology practice: Past, present and future","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}